Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH MEDIA
GLOBETECH PUBLISHING LLC
GLOBETECH PUBLISHING LLC

Gene Therapy Increases Survival in Huntington's Disease Animal Models

By BiotechDaily International staff writers
Posted on 27 Jun 2013
Gene therapy that suppressed formation of glial cells while promoting growth of neurons in the adult brain slowed development of neurodegenerative Huntington's disease in animal models.

Huntington’s disease (HD) is caused by a dominant gene that encodes the huntingtin protein. The 5' end of the HD gene has a sequence of three DNA bases, cytosine-adenine-guanine (CAG), coding for the amino acid glutamine, that is repeated multiple times. Normal persons have a CAG repeat count of between 7 and 35 repeats, while the mutated form of the gene has anywhere from 36 to 180 repeats. The mutant form of huntingtin is broken down into toxic peptides, which cause the loss of a type of brain cell called striatopallidal medium spiny projection neurons (MSNs). Destruction of these cells causes involuntary movements, problems with coordination, and, ultimately, in cognitive decline and depression. There is currently no treatment for this fatal disease.

Investigators at the University of Rochester Medical Center (NY, USA) and their colleagues at the University of Iowa (Iowa City, USA) initially worked with a Huntington's disease mouse model. They injected these animals with adeno-associated viruses (AAVs) modified to deliver the genes for the proteins BDNF (brain derived neurotrophic factor) or noggin. BDNF stimulates neural stem cells to produce neurons, while noggin inhibits the molecular pathway that induces formation of glial cells.

Results reported in the June 6, 2013, issue of the journal Cell Stem Cell revealed that a single injection of the adeno-associated viruses AAV4-BDNF and AAV4-noggin triggered the sustained recruitment of new MSNs in wild-type and R6/2 mice, a Huntington's disease model. Mice treated with AAV4-BDNF/noggin or with BDNF and noggin proteins actively recruited progenitor cells to form new MSNs that matured and achieved circuit integration. The AAV4-BDNF/noggin-treated R6/2 mice showed delayed deterioration of motor function and substantially increased survival.

In a follow-up set of experiments, squirrel monkeys that were given injections of adenoviral BDNF/noggin showed similar addition of striatal neurons.

"This study demonstrates the feasibility of a completely new concept to treat Huntington's disease, by recruiting the brain's endogenous neural stem cells to regenerate cells lost to the disease," said senior author Dr. Steve Goldman, professor of neurology at the University of Rochester Medical Center. "The sustained delivery of BDNF and noggin into the adult brain was clearly associated with both increased neurogenesis and delayed disease progression. We believe that our data suggest the feasibility of this process as a viable therapeutic strategy for Huntington's disease."

Related Links:
University of Rochester Medical Center
University of Iowa



Channels

Drug Discovery

view channel
Image: Molecular model of the protein Saposin C (Photo courtesy of Wikimedia Commons).

Nanovesicles Kill Human Lung Cancer Cells in Culture and in a Mouse Xenograft Model

Nanovesicles assembled from the protein Saposin C (SapC) and the phospholipid dioleoylphosphatidylserine (DOPS) were shown to be potent inhibitors of lung cancer cells in culture and in a mouse xenograft model.... Read more

Biochemistry

view channel

Possible New Target Found for Treating Brain Inflammation

Scientists have identified an enzyme that produces a class of inflammatory lipid molecules in the brain. Abnormally high levels of these molecules appear to cause a rare inherited eurodegenerative disorder, and that disorder now may be treatable if researchers can develop suitable drug candidates that suppress this enzyme.... Read more

Lab Technologies

view channel
Image: The FLUOVIEW FVMPE-RS Gantry microscope (Photo courtesy of Olympus).

New Multiphoton Laser Scanning Microscope Configurations Expand Research Potential

Two new configurations of a state-of-the-art multiphoton laser scanning microscope extend the usefulness of the instrument for examining rapidly occurring biological events and for obtaining images from... Read more

Business

view channel

Roche Acquires Signature Diagnostics to Advance Translational Research

Roche (Basel, Switzerland) will advance translational research for next generation sequencing (NGS) diagnostics by leveraging the unique expertise of Signature Diagnostics AG (Potsdam, Germany) in biobanks and development of novel NGS diagnostic assays. Signature Diagnostics is a privately held translational oncology... Read more
 
Copyright © 2000-2015 Globetech Media. All rights reserved.